{
  "nctId": "NCT06960213",
  "title": "STOP-HAE: A Phase 3 Study of ADX-324 in HAE",
  "sponsor": "ADARx Pharmaceuticals, Inc.",
  "phase": "Phase 3",
  "status": "RECRUITING",
  "condition": "Hereditary angioedema",
  "enrollment": {
    "count": 90,
    "type": "ESTIMATED"
  },
  "primaryCompletion": {
    "date": "2027-11-30",
    "type": "ESTIMATED"
  },
  "lastUpdatePosted": "2026-09-10",
  "checkedAt": "2026-09-11T21:42:16.673Z",
  "source": "https://clinicaltrials.gov/study/NCT06960213",
  "scope": "Public registry snapshot; not a confirmed outsourcing opportunity. No previous version was compared."
}